Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Adam on +44 1494 818010 or adam@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Adam Woolley
Recruitment Consultant
adam@zenopa.com
+44 1494 818010

Testimonials
Zenopa gave a fast and friendly service, with very good communication. They followed up every step of the way with either a phone call or an e-mail to see how things were going.
Damien, 2013

Sanofi and MMV to develop malaria treatments

9 May 2011 00:00 in Pharmaceutical Company Product News


Sanofi has announced plans to ally with the not-for-profit organisation Medicines for Malaria Venture (MMV) on the development of new treatments for the tropical disease.

The three-year research project will be called Orthology Malaria and involves the creation of drug candidates based on Sanofi compounds chosen for their potential efficacy, with proof of concept trials among males to follow.

At each stage of this programme, a joint steering committee will evaluate the project's status in accordance with compound progression criteria devised by MMV.

This comes as part of a wider malaria-focused alliance between the two organisations, which was signed earlier this year.

Dr Elias Zerhouni, president of global research and development at Sanofi, said: "This new partnership will enable us to mobilise each organisation's expertise, resources and know-how to identify novel medicines for malaria patients."

The company's shareholders voted to change its name from Sanofi-aventis to Sanofi this month, a move designed to make the brand simpler and easier to remember and pronounce.ADNFCR-8000103-ID-800523678-ADNFCR

Other news stories from 09/05/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd